Physician profile
Debbie Wright-Thomasson
NPI 1235151432
$1,610.72
in general payments reported to CMS, 2019-2025
25 companies · $87.47 in 2025
The $87.47 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $182 · 2021: $146 · 2022: $16.62 · 2023: $129 · 2024: $854 · 2025: $87.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $169.95 | 2019-2024 | Cardiomems |
| Janssen Pharmaceuticals, INC | $167.46 | 2019-2024 | Xarelto |
| Gilead Sciences, INC. | $150.00 | 2024 | |
| Amgen INC. | $148.53 | 2019-2024 | Repatha |
| Pfizer INC. | $143.64 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.52 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $96.72 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $87.69 | 2020-2024 | Farxiga, Wainua |
| Lexicon Pharmaceuticals, INC. | $72.92 | 2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $64.10 | 2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $56.23 | 2024 | Wegovy, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.68 | 2023-2024 | Lifevest |
| Bridgebio Pharma, INC. | $36.78 | 2025 | Attruby |
| Scpharmaceuticals INC. | $35.44 | 2024 | |
| Cvrx, INC. | $32.12 | 2023-2024 | Barostim Neo System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $30.35 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $28.83 | 2024 | Eliquis |
| Medtronic, INC. | $21.26 | 2024 | Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $18.38 | 2024 | Verquvo |
| Irhythm Technologies, INC. | $18.00 | 2023 | Zio Xt Patch |
| Medtronic Vascular, INC. | $17.54 | 2020 | |
| Astellas Pharma US INC | $15.06 | 2025 | Veozah |
| Cardiofocus, INC. | $14.20 | 2019 | |
| Glaxosmithkline, LLC. | $12.84 | 2019 | |
| Abiomed | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Wright-Thomasson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.